Macimorelin

CHEMBL278623 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
474.6 g/mol
LogP
1.8
Phase
4

A synthetic growth hormone secretagogue used as a diagnostic agent to test for adult growth hormone deficiency by stimulating the release of growth hormone from the pituitary gland. It is taken orally before a blood test to measure the body's growth hormone response.

Molekularmasse

474,6000 g/mol

LogP

1,80

TPSA

145,00 Ų

Lipinski-Regel der Fünf

Bestanden

Wirkmechanismus

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)(N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1c[nH]c2ccccc12)NC=O

InChI

InChI=1S/C26H30N6O3/c1-26(2,27)25(35)31-22(11-16-13-28-20-9-5-3-7-18(16)20)24(34)32-23(30-15-33)12-17-14-29-21-10-6-4-8-19(17)21/h3-10,13-15,22-23,28-29H,11-12,27H2,1-2H3,(H,30,33)(H,31,35)(H,32,34)/t22-,23-/m1/s1

Molecular Formula

C26H30N6O3

HBD / HBA

6 / 4

Rotierbare Bindungen

9

Schwere Atome

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A synthetic growth hormone secretagogue used as a diagnostic agent to test for adult growth hormone deficiency by stimulating the release of growth hormone from the pituitary gland. It is taken orally before a blood test to measure the body's growth hormone response.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Macimorelin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL278623. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9804938. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.